Literature DB >> 19105186

Identification of novel mutations and sequence variation in the Zellweger syndrome spectrum of peroxisome biogenesis disorders.

Wing Yan Yik1, Steven J Steinberg, Ann B Moser, Hugo W Moser, Joseph G Hacia.   

Abstract

Peroxisome biogenesis disorders (PBD) are a heterogeneous group of autosomal recessive neurodegenerative disorders that affect multiple organ systems. Approximately 80% of PBD patients are classified in the Zellweger syndrome spectrum (PBD-ZSS). Mutations in the PEX1, PEX6, PEX10, PEX12, or PEX26 genes are found in approximately 90% of PBD-ZSS patients. Here, we sequenced the coding regions and splice junctions of these five genes in 58 PBD-ZSS cases previously subjected to targeted sequencing of a limited number of PEX gene exons. In our cohort, 71 unique sequence variants were identified, including 18 novel mutations predicted to disrupt protein function and 2 novel silent variants. We identified 4 patients who had two deleterious mutations in one PEX gene and a third deleterious mutation in a second PEX gene. For two such patients, we conducted cell fusion complementation analyses to identify the defective gene responsible for aberrant peroxisome assembly. Overall, we provide empirical data to estimate the relative fraction of disease-causing alleles that occur in the coding and splice junction sequences of these five PEX genes and the frequency of cases where mutations occur in multiple PEX genes. This information is beneficial for efforts aimed at establishing rapid and sensitive clinical diagnostics for PBD-ZSS patients and interpreting the results from these genetic tests. 2008 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19105186      PMCID: PMC2649967          DOI: 10.1002/humu.20932

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  50 in total

Review 1.  Peroxisome biogenesis.

Authors:  P E Purdue; P B Lazarow
Journal:  Annu Rev Cell Dev Biol       Date:  2001       Impact factor: 13.827

2.  Oligonucleotide microarray based detection of repetitive sequence changes.

Authors:  J G Hacia; K Edgemon; N Fang; R A Mayer; D Sudano; N Hunt; F S Collins
Journal:  Hum Mutat       Date:  2000-10       Impact factor: 4.878

3.  Biochemical markers predicting survival in peroxisome biogenesis disorders.

Authors:  J Gootjes; P A W Mooijer; C Dekker; P G Barth; B T Poll-The; H R Waterham; R J A Wanders
Journal:  Neurology       Date:  2002-12-10       Impact factor: 9.910

4.  Molecular anatomy of the peroxin Pex12p: ring finger domain is essential for Pex12p function and interacts with the peroxisome-targeting signal type 1-receptor Pex5p and a ring peroxin, Pex10p.

Authors:  K Okumoto; I Abe; Y Fujiki
Journal:  J Biol Chem       Date:  2000-08-18       Impact factor: 5.157

5.  Novel PEX1 mutations and genotype-phenotype correlations in Australasian peroxisome biogenesis disorder patients.

Authors:  Megan A Maxwell; Tamara Allen; Pamela B Solly; Terje Svingen; Barbara C Paton; Denis I Crane
Journal:  Hum Mutat       Date:  2002-11       Impact factor: 4.878

6.  PEX1 mutations in complementation group 1 of Zellweger spectrum patients correlate with severity of disease.

Authors:  Natalie Preuss; Ute Brosius; Martina Biermanns; Ania C Muntau; Ernst Conzelmann; Jutta Gartner
Journal:  Pediatr Res       Date:  2002-06       Impact factor: 3.756

7.  Disorders of peroxisome biogenesis due to mutations in PEX1: phenotypes and PEX1 protein levels.

Authors:  C Walter; J Gootjes; P A Mooijer; H Portsteffen; C Klein; H R Waterham; P G Barth; J T Epplen; W H Kunau; R J Wanders; G Dodt
Journal:  Am J Hum Genet       Date:  2001-06-01       Impact factor: 11.025

8.  Investigational methods for peroxisomal disorders.

Authors:  Steven Steinberg; Richard Jones; Carol Tiffany; Ann Moser
Journal:  Curr Protoc Hum Genet       Date:  2008-07

9.  Genetic heterogeneity of peroxisome biogenesis disorders among Japanese patients: evidence for a founder haplotype for the most common PEX10 gene mutation.

Authors:  Nobuyuki Shimozawa; Tomoko Nagase; Yasuhiko Takemoto; Toshihiro Ohura; Yasuyuki Suzuki; Naomi Kondo
Journal:  Am J Med Genet A       Date:  2003-07-01       Impact factor: 2.802

10.  PEX12 interacts with PEX5 and PEX10 and acts downstream of receptor docking in peroxisomal matrix protein import.

Authors:  C C Chang; D S Warren; K A Sacksteder; S J Gould
Journal:  J Cell Biol       Date:  1999-11-15       Impact factor: 10.539

View more
  23 in total

Review 1.  Peroxisome biogenesis disorders in the Zellweger spectrum: An overview of current diagnosis, clinical manifestations, and treatment guidelines.

Authors:  Nancy E Braverman; Gerald V Raymond; William B Rizzo; Ann B Moser; Mark E Wilkinson; Edwin M Stone; Steven J Steinberg; Michael F Wangler; Eric T Rush; Joseph G Hacia; Mousumi Bose
Journal:  Mol Genet Metab       Date:  2015-12-23       Impact factor: 4.797

2.  Allelic Expression Imbalance Promoting a Mutant PEX6 Allele Causes Zellweger Spectrum Disorder.

Authors:  Kim D Falkenberg; Nancy E Braverman; Ann B Moser; Steven J Steinberg; Femke C C Klouwer; Agatha Schlüter; Montserrat Ruiz; Aurora Pujol; Martin Engvall; Karin Naess; FrancJan van Spronsen; Irene Körver-Keularts; M Estela Rubio-Gozalbo; Sacha Ferdinandusse; Ronald J A Wanders; Hans R Waterham
Journal:  Am J Hum Genet       Date:  2017-12-07       Impact factor: 11.025

3.  Nonsense suppressor therapies rescue peroxisome lipid metabolism and assembly in cells from patients with specific PEX gene mutations.

Authors:  Patricia K Dranchak; Erminia Di Pietro; Ann Snowden; Nathan Oesch; Nancy E Braverman; Steven J Steinberg; Joseph G Hacia
Journal:  J Cell Biochem       Date:  2011-05       Impact factor: 4.429

4.  Two novel mutations of PEX6 in one Chinese Zellweger spectrum disorder and their clinical characteristics.

Authors:  Hui-Ling Yu; Yan Shen; Yi-Min Sun; Yue Zhang
Journal:  Ann Transl Med       Date:  2019-08

5.  Clinical, neuroradiological, and molecular characterization of patients with atypical Zellweger spectrum disorder caused by PEX16 mutations: a case series.

Authors:  Anthony Cheung; Catherine Argyriou; Christine Yergeau; Yasmin D'Souza; Émilie Riou; Sébastien Lévesque; Gerald Raymond; Mebratu Daba; Irakli Rtskhiladze; Tinatin Tkemaladze; Laura Adang; Roberta La Piana; Geneviève Bernard; Nancy Braverman
Journal:  Neurogenetics       Date:  2022-02-02       Impact factor: 2.660

6.  Identification of differences in human and great ape phytanic acid metabolism that could influence gene expression profiles and physiological functions.

Authors:  Paul A Watkins; Ann B Moser; Cicely B Toomer; Steven J Steinberg; Hugo W Moser; Mazen W Karaman; Krishna Ramaswamy; Kimberly D Siegmund; D Rick Lee; John J Ely; Oliver A Ryder; Joseph G Hacia
Journal:  BMC Physiol       Date:  2010-10-08

7.  A Drosophila model for the Zellweger spectrum of peroxisome biogenesis disorders.

Authors:  Fred D Mast; Jing Li; Maninder K Virk; Sarah C Hughes; Andrew J Simmonds; Richard A Rachubinski
Journal:  Dis Model Mech       Date:  2011-06-13       Impact factor: 5.758

8.  Characterization of two common 5' polymorphisms in PEX1 and correlation to survival in PEX1 peroxisome biogenesis disorder patients.

Authors:  Sven Thoms; Sabine Grønborg; Jana Rabenau; Andreas Ohlenbusch; Hendrik Rosewich; Jutta Gärtner
Journal:  BMC Med Genet       Date:  2011-08-16       Impact factor: 2.103

9.  The gene expression profiles of induced pluripotent stem cells from individuals with childhood cerebral adrenoleukodystrophy are consistent with proposed mechanisms of pathogenesis.

Authors:  Xiao-Ming Wang; Wing Yan Yik; Peilin Zhang; Wange Lu; Patricia K Dranchak; Darryl Shibata; Steven J Steinberg; Joseph G Hacia
Journal:  Stem Cell Res Ther       Date:  2012-10-04       Impact factor: 6.832

10.  Diverse captive non-human primates with phytanic acid-deficient diets rich in plant products have substantial phytanic acid levels in their red blood cells.

Authors:  Ann B Moser; Jody Hey; Patricia K Dranchak; Mazen W Karaman; Junsong Zhao; Laura A Cox; Oliver A Ryder; Joseph G Hacia
Journal:  Lipids Health Dis       Date:  2013-02-04       Impact factor: 3.876

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.